You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昭衍新藥(06127.HK)公佈中期業績:營收超10億元同比增長30.3%,研發開支同比大增123.4%,維持強勁的流動資金

格隆匯8月30日丨昭衍新藥(06127.HK)公佈中期業績,截至2023年6月30日止六個月,公司收益為人民幣10.12億元,同比增長30.3%;毛利為人民幣4.48億元,同比增長18.5%。收益及毛利增加主要由於業務擴展所致。研發開支為人民幣5690萬元,同比增長123.4%。於2023年6月30日,現金及現金等價物為人民幣30.405億元,仍維持強勁的流動資金。

報吿期內,期內溢利為人民幣8950.8萬元,淨利潤有所下降主要原因如下:報吿期實驗室服務業務依然保持穩定增長,貢獻淨利潤為人民幣1.95億元。該期生物資產公允價值變動帶來的淨損失為人民幣1.83億元。

未來,公司能夠將透過提升技術能力,以滿足日益增長的創新藥的藥物安全性評價及其他非臨牀服務需求,繼續鞏固在藥物安全性評價市場的市場領導地位。具體而言,公司計劃專注於在最大行業需求領域(例如大分子生物分析以及細胞及基因療法)中增強競爭優勢。公司計劃透過招募在相關領域擁有豐富經驗的合資格科研專業人員及開發及購置先進設備及技術升級我們的實驗室,以執行該等策略。

鑑於客户需求不斷增加,公司亦將透過建立新設施及擴大、翻新及升級現有設施來擴大服務能力。具體而言,蘇州昭衍II期20,000平米設施已完成佈局規劃,其中12,000平米設施已在進行施工設計,預計2023年下半年陸續投入使用;按照公司的戰略規劃,廣州昭衍安評基地的建設也在有序進行中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account